(Source: Xencor Inc) MONROVIA, Calif., May 14, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first quarter ended March 31, 2014 and provided a review of recent business highlights. "We have continued to advance our drug development programs and we plan to have preliminary data from both of our lead programs, XmAb7195 and XmAb5871, in the second half of 2014," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "In addition to the progress in our lead...
↧
